| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥161.7B | ¥209.4B | -22.7% |
| Operating Income | ¥4.9B | ¥6.0B | -18.7% |
| Ordinary Income | ¥6.5B | ¥7.7B | -15.4% |
| Net Income | ¥2.0B | ¥5.1B | -60.4% |
| ROE | 1.9% | 4.8% | - |
FY2025 Q3 cumulative results show revenue of 161.7B yen (YoY -22.7%), operating income of 4.9B yen (YoY -18.7%), ordinary income of 6.5B yen (YoY -15.4%), and net income of 2.0B yen (YoY -60.4%). The significant revenue decline was accompanied by margin compression, with operating margin at 3.0% and net profit margin at 1.3%. The extraordinary drop in net income from 5.1B yen to 2.0B yen reflects a combination of high effective tax rate of 47.8% and special losses of 2.6B yen related to equity changes following subsidiary deconsolidation. Total assets remained stable at 222.2B yen with equity of 105.2B yen, maintaining an equity ratio of 47.4%. ROE declined to 1.9% from prior year levels, driven by compressed profitability across all margin metrics.
Revenue decreased 47.7B yen YoY to 161.7B yen, representing a 22.7% decline primarily driven by structural changes in the reporting scope and underlying demand weakness in the injection molding business. The prior period included Americas injection molding operations as a consolidated subsidiary, which transitioned to equity method accounting in Q1 following a third-party capital injection. The Japanese injection molding business, which forms the core operations, recorded sales of 155.7B yen in the current period. Gross profit declined to 29.8B yen with gross margin of 18.4%, down from higher prior year levels, indicating pricing pressure or unfavorable product mix. SG&A expenses of 24.9B yen remained relatively fixed despite the revenue decline, resulting in an increased SG&A ratio of 15.4% and operating income compression to 4.9B yen.
Non-operating income contributed 1.6B yen net positive between operating income and ordinary income, comprising interest and dividend income of 0.58B yen, equity method gains of 0.39B yen, and foreign exchange gains of 0.51B yen. This 1.6B yen bridge partially offset the operating profit decline. The gap between ordinary income of 6.5B yen and net income of 2.0B yen widened significantly to 4.5B yen due to two primary factors: special losses of 2.6B yen (predominantly loss on change in equity of 2.58B yen from the subsidiary restructuring) and an exceptionally high effective tax rate of 47.8% on pre-tax income of 3.9B yen. This represents non-recurring impact from the Americas subsidiary deconsolidation and potential adjustments in tax positions. The business pattern is revenue down, profit down, with declining margins across all levels of the P&L.
The company operates three reporting segments following restructuring. Injection Molding Business in Japan is the core business, generating sales of 155.7B yen (96.2% of total segment sales) and operating income of 3.09B yen with a margin of 2.0%. This segment increased sales by 6.5B yen from prior period's 149.2B yen and improved operating profit from 1.92B yen, demonstrating operational recovery in the domestic market. Injection Molding Business in China recorded sales of 0.43B yen with operating income of 4 million yen (0.9% margin), a contraction from prior period sales of 0.45B yen and an improvement from prior period operating loss of 13 million yen. Real Estate segment contributed stable sales of 0.21B yen with operating income of 0.17B yen (81.0% margin), slightly declining from prior period profit of 0.19B yen. The Americas segment, previously reporting 53.5B yen in sales with 2.30B yen operating profit, is no longer consolidated and now reported under equity method, explaining the majority of the consolidated revenue decline. The domestic injection molding business clearly represents the core operations with dominant scale, though its low 2.0% margin highlights significant profitability challenges requiring cost structure improvement and pricing power recovery.
[Profitability] ROE of 1.9% represents a material decline from historical levels, with operating margin of 3.0% and net profit margin of 1.3% both indicating compressed profitability. The effective tax rate of 47.8% substantially exceeded normal corporate tax rates, depressing net income. Gross profit margin of 18.4% suggests limited pricing power or unfavorable cost structure. [Cash Quality] Cash and deposits of 38.7B yen provide coverage of 46.1 times against short-term debt of 1.0B yen, indicating strong immediate liquidity. [Investment Efficiency] Asset turnover of 0.73 (calculated as 161.7B yen revenue over 222.2B yen average total assets) exceeds the industry median of 0.56, suggesting relatively efficient asset utilization despite revenue headwinds. [Financial Health] Equity ratio of 47.4% reflects moderate capital stability, current ratio of 119.6% (100.4B yen current assets over 83.9B yen current liabilities) provides adequate short-term solvency though below typical benchmarks. Debt-to-equity ratio of 0.24 (25.4B yen interest-bearing debt over 105.2B yen equity) indicates conservative leverage, with interest coverage of 14.3 times demonstrating sufficient debt servicing capacity.
Cash and deposits declined 0.4B yen YoY from 39.1B yen to 38.7B yen, reflecting modest cash consumption despite positive net income of 2.0B yen. The stable cash position suggests operating activities generated sufficient cash to offset investment and financing activities, though specific cash flow statement details are not disclosed for the quarterly period. Working capital position shows 16.5B yen in net current assets (current assets minus current liabilities), with trade receivables of 26.4B yen and electronically recorded monetary claims of 18.7B yen representing 27.9% of total assets, indicating normal business cycle requirements. Electronically recorded obligations of 29.4B yen demonstrate effective use of trade payables for working capital management. The balance sheet structure with 38.7B yen cash against 25.4B yen total interest-bearing debt yields net cash position of 13.3B yen, providing financial flexibility. Short-term debt coverage by cash stands at 38.7 times, confirming robust liquidity despite the quarterly profit decline.
Ordinary income of 6.5B yen compared to operating income of 4.9B yen reflects net non-operating contribution of 1.6B yen, comprising equity method investment gains of 0.39B yen, interest and dividend income of 0.58B yen, and foreign exchange gains of 0.51B yen. Non-operating income represents 1.0% of revenue, indicating modest reliance on non-core sources. The material 4.5B yen gap between ordinary income and net income warrants attention: special losses totaled 2.6B yen (primarily 2.58B yen loss on change in equity related to subsidiary restructuring), representing a non-recurring item. Additionally, the effective tax rate of 47.8% significantly exceeds Japan's statutory corporate tax rate, suggesting either non-deductible expenses related to the restructuring or adjustments to deferred tax positions. Excluding these non-recurring factors, normalized net income would approximate 4.1B yen (ordinary income of 6.5B yen less normalized 37% tax), implying the 2.0B yen reported net income was depressed by approximately 2.1B yen from temporary factors. Operating cash flow data is not available for quarterly assessment, limiting full earnings quality evaluation, though the stable cash position relative to reported earnings suggests reasonable cash conversion under normal circumstances.
Full-year guidance projects revenue of 220.0B yen, operating income of 6.0B yen, ordinary income of 7.0B yen, and net income of 2.5B yen. Q3 cumulative progress rates stand at 73.5% for revenue (161.7B yen of 220.0B yen target), 81.0% for operating income (4.9B yen of 6.0B yen target), 93.0% for ordinary income (6.5B yen of 7.0B yen target), and 81.2% for net income (2.0B yen of 2.5B yen target). Revenue progress of 73.5% against the standard 75% Q3 benchmark indicates slightly behind-pace performance, requiring Q4 revenue of 58.3B yen or approximately 36% of full-year total in the final quarter. Operating income progress of 81.0% appears ahead of schedule, suggesting conservative full-year guidance or stronger Q4 margins. Ordinary income progress of 93.0% is substantially ahead, implying Q4 ordinary income of only 0.5B yen, which may reflect expected reduction in non-operating gains or one-time Q3 benefits. The significant divergence between ordinary income (93.0% achieved) and net income (81.2% achieved) guidance progress reflects the Q3 special losses and high tax rate, with full-year guidance implying Q4 normalized tax burden. The company targets EPS of 14.69 yen for the full year compared to Q3 cumulative EPS of 11.93 yen.
The company plans a year-end dividend of 5.00 yen per share with no interim dividend, representing total annual dividend of 5.00 yen. Based on the forecasted full-year EPS of 14.69 yen, the payout ratio is 34.0%. Using actual Q3 cumulative net income of 2.0B yen and outstanding shares of 17.01 million, the calculated annual payout ratio based on current earnings is 42.6% (5.00 yen times 17.01 million shares divided by 2.0B yen net income). The prior period dividend information is not disclosed, preventing YoY comparison. With cash reserves of 38.7B yen and conservative financial leverage, the 85 million yen total dividend commitment (5.00 yen times 17.01 million shares) represents only 2.2% of cash holdings, indicating comfortable dividend coverage and sustainability even under current compressed profitability. No share buyback programs are disclosed in the available data.
Demand contraction risk: Revenue declined 22.7% YoY with the core Japanese injection molding segment showing only modest recovery, indicating vulnerability to sustained weakness in end-market demand from automotive, industrial, or logistics customers, which could further pressure already thin 3.0% operating margins.
Margin compression and pricing power risk: Gross margin of 18.4% combined with 3.0% operating margin ranks significantly below industry benchmarks, reflecting limited ability to pass through cost increases or unfavorable product mix, with fixed SG&A of 24.9B yen creating operating leverage risk if revenues decline further.
Tax and profitability volatility risk: The 47.8% effective tax rate in Q3 and 2.6B yen special loss from equity restructuring demonstrate earnings volatility from non-operating factors, with ROE of 1.9% and ROIC of 2.8% indicating insufficient returns on invested capital that constrain reinvestment capacity and shareholder value creation.
[Industry Position] (Reference - Proprietary Analysis)
The company's profitability metrics significantly underperform manufacturing sector benchmarks. Operating margin of 3.0% falls well below the industry median of 8.9% (IQR: 5.4%-12.7%), ranking in the bottom quartile of peer companies. Net profit margin of 1.3% similarly trails the industry median of 6.5% (IQR: 3.3%-9.4%), reflecting both operational challenges and the impact of exceptional tax burden. ROE of 1.9% substantially lags the industry median of 5.8% (IQR: 3.1%-8.4%), indicating materially weaker returns to shareholders compared to sector peers.
Financial health metrics present a mixed picture. The equity ratio of 47.4% sits below the industry median of 63.8% (IQR: 49.1%-74.8%), placing the company in the lower half of peers on capital stability. However, the current ratio of 119.6% falls significantly short of the industry median of 287% (IQR: 213%-384%), suggesting tighter liquidity management relative to peers. Asset turnover of 0.73 exceeds the industry median of 0.56 (IQR: 0.41-0.65), representing a relative strength in asset efficiency despite revenue headwinds.
Growth metrics show considerable weakness. Revenue growth of -22.7% contrasts sharply with the industry median of +2.8% (IQR: -1.5% to +8.8%), though this largely reflects the structural impact of subsidiary deconsolidation. ROIC of 2.8% trails the industry median of 6.0% (IQR: 3.0%-10.0%), highlighting insufficient investment returns. Financial leverage of 2.11x exceeds the industry median of 1.53x (IQR: 1.31-1.86), though absolute debt levels remain manageable given strong cash reserves.
(Industry: Manufacturing sector, N=105 companies, Comparison: 2025-Q3 period, Source: Proprietary analysis)
Profitability recovery imperative: The company's 3.0% operating margin and 1.9% ROE represent the most critical performance gap versus industry benchmarks (8.9% and 5.8% medians respectively), requiring urgent focus on cost structure optimization, pricing discipline, and product mix improvement to restore competitive returns on capital. The 18.4% gross margin provides limited buffer for operating leverage improvement.
One-time charges masking core performance: The 60.4% YoY decline in net income reflects substantial non-recurring impacts including 2.6B yen in special losses from subsidiary restructuring and an abnormally high 47.8% effective tax rate, which together reduced net income by approximately 2.1B yen. Normalizing for these factors suggests underlying earning power closer to 4.1B yen, though still reflecting compressed margins requiring operational improvement.
Financial position provides stability for turnaround: Despite weak profitability, the balance sheet maintains 38.7B yen in cash against 25.4B yen in interest-bearing debt, creating a 13.3B yen net cash position with debt-to-equity of only 0.24. This financial flexibility, combined with asset turnover of 0.73 exceeding the industry median of 0.56, provides management with resources and time to execute margin recovery initiatives without immediate capital constraints.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.